For a patient with atrial fibrillation taking an 800 mg loading dose of amiodarone, how many days until they can switch to a maintenance dose and what is the typical maintenance dose?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Amiodarone Loading and Maintenance Dosing for Atrial Fibrillation

For a patient taking 800 mg daily amiodarone loading dose for atrial fibrillation, continue this dose for 1 week (7 days), then transition to a maintenance dose of 200-400 mg daily, with 200 mg daily being the preferred long-term dose to minimize toxicity. 1, 2

Loading Duration and Taper Protocol

The standard outpatient loading regimen follows a structured approach:

  • Week 1: Continue 600-800 mg daily in divided doses 1, 2
  • Weeks 2-4: Reduce to 400-600 mg daily 1
  • Weeks 5-6: Further reduce to 200-400 mg daily 1
  • Maintenance (after week 6): 200 mg daily is the standard long-term dose 1, 2

An alternative loading approach recommended by the ACC/AHA guidelines is 600 mg daily for one month OR 1000 mg daily for one week, followed by maintenance dosing 2. However, the 6-week taper protocol provides a more gradual transition that may reduce side effects 1.

Maintenance Dose Selection

The maintenance dose should be 200 mg daily or less to minimize toxicity while maintaining efficacy. 3, 2 Low-dose amiodarone (200 mg daily or less) is effective and associated with fewer side effects than higher-dose regimens 3, 2. While maintenance doses can range from 100-400 mg daily, the 200 mg dose represents the optimal balance between efficacy and safety for most patients with atrial fibrillation 1, 2.

Critical Monitoring During Loading and Transition

During the loading phase and dose transitions, specific monitoring is essential:

  • Cardiac monitoring: Check heart rate approximately weekly, and assess PR interval, QRS duration, and QT interval after each dose change 2
  • Bradycardia surveillance: If bradycardia develops (occurs in 1-3% of patients), immediately reduce the dose to 200 mg every 24 hours 1
  • Conduction abnormalities: Watch for hypotension and AV block during initiation 2

Drug Interaction Management

Adjust concomitant medications proactively during amiodarone loading:

  • Warfarin: Reduce dose by 30-50% as amiodarone significantly increases INR 1, 2
  • Digoxin: Reduce dose by 30-50% as amiodarone doubles digoxin levels 1, 2
  • Other rate-control agents: Reduce doses as amiodarone's rate-control effect develops 2

Long-Term Monitoring on Maintenance Therapy

Once on maintenance dosing, continue surveillance for serious toxicity:

  • Monitor thyroid function, liver enzymes, and pulmonary function every 3-6 months 1
  • Serious long-term toxicity can develop even at low doses of 200 mg daily 1
  • Approximately 18% of patients discontinue amiodarone due to side effects, with pulmonary fibrosis, neurological toxicity, and hepatic dysfunction being most serious 2

Common Pitfalls to Avoid

Do not rush the loading phase. Amiodarone has an elimination half-life of approximately 30 days (range 15-100 days), meaning maximal effects are not attained before 90-150 days of treatment 4. The pretherapeutic latency period varies by arrhythmia type and dose employed 4.

Do not maintain high doses long-term. While loading doses of 800 mg daily are appropriate initially 5, 6, continuing high doses (400-600 mg daily) long-term significantly increases the risk of adverse effects, which occur in approximately 50% of patients on high-dose therapy 5. The 200 mg daily maintenance dose provides effective rhythm control with substantially lower toxicity 3, 2.

References

Guideline

Amiodarone Taper for Atrial Tachycardia Over 6 Weeks

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Amiodarone Dosing for Atrial Fibrillation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Ten years of experience with amiodarone.

American heart journal, 1983

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.